Authors: Longfei Jia, Qiongqiong Qiu, Heng Zhang, Lan Chu, Yifeng Du, Jiewen Zhang, Chunkui Zhou, Furu Liang, Shengliang Shi, Shan Wang, Wei Qin, Qi Wang, Fangyu Li, Qigeng Wang, Yan Li, Luxi Shen, Yiping Wei, Jianping Jia
Published: 2019-08-15
DOI: 10.1016/j.jalz.2019.05.002
Source: Full article
AbstractIntroductionNeuronal‐derived exosomal Aβ42, T‐tau, and P‐T181‐tau have been demonstrated to be biomarkers of Alzheimer's disease (AD). However, no study has assessed the association of Aβ42, T‐tau, and P‐T181‐tau between exosomes and CSF.MethodsThis was a multicenter study with two‐stage design. The subjects included 28 AD patients, 25 aMCI patients, and 29 controls in the discovery stage; the results of which were confirmed in the validation stage (73 AD, 71 aMCI, and 72 controls).ResultsThe exosomal concentrations of Aβ42, T‐tau, and P‐T181‐tau in AD group were higher than those in aMCI and control groups (all P < .001). The level of each exosomal biomarker was highly correlated with that in CSF.DiscussionThis study verified the agreement between CSF and blood exosomal biomarkers and confirmed that exosomal Aβ42, T‐tau, and P‐T181‐tau have the same capacity as those in CSF for the diagnosis of AD and aMCI.